Cargando…

In Vitro and In Silico Investigation of BCI Anticancer Properties and Its Potential for Chemotherapy-Combined Treatments

SIMPLE SUMMARY: BCI is an allosteric inhibitor of DUSP6 phosphatase, which is a negative regulator of MAPK kinases involved in numerous cellular processes such as proliferation, differentiation, and survival. These studies were designed to test the anticancer potential of BCI in colorectal cancer (C...

Descripción completa

Detalles Bibliográficos
Autores principales: Marciniak, Beata, Kciuk, Mateusz, Mujwar, Somdutt, Sundaraj, Rajamanikandan, Bukowski, Karol, Gruszka, Renata
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10526149/
https://www.ncbi.nlm.nih.gov/pubmed/37760412
http://dx.doi.org/10.3390/cancers15184442
_version_ 1785110953279356928
author Marciniak, Beata
Kciuk, Mateusz
Mujwar, Somdutt
Sundaraj, Rajamanikandan
Bukowski, Karol
Gruszka, Renata
author_facet Marciniak, Beata
Kciuk, Mateusz
Mujwar, Somdutt
Sundaraj, Rajamanikandan
Bukowski, Karol
Gruszka, Renata
author_sort Marciniak, Beata
collection PubMed
description SIMPLE SUMMARY: BCI is an allosteric inhibitor of DUSP6 phosphatase, which is a negative regulator of MAPK kinases involved in numerous cellular processes such as proliferation, differentiation, and survival. These studies were designed to test the anticancer potential of BCI in colorectal cancer (CRC) cells and assess its interaction with chemotherapuetics such as irinotecan and oxaliplatin. In silico investigations were performed to indicate new possible molecular targets, which in the future will help toward understanding the precise mechanism of action. ABSTRACT: Background: DUSP6 phosphatase serves as a negative regulator of MAPK kinases involved in numerous cellular processes. BCI has been identified as a potential allosteric inhibitor with anticancer activity. Our study was designed to test the anticancer properties of BCI in colon cancer cells, to characterize the effect of this compound on chemotherapeutics such as irinotecan and oxaliplatin activity, and to identify potential molecular targets for this inhibitor. Methods: BCI cytotoxicity, proapoptotic activity, and cell cycle distribution were investigated in vitro on three colon cancer cell lines (DLD1, HT-29, and Caco-2). In silico investigation was prepared to assess BCI drug-likeness and identify potential molecular targets. Results: The exposure of colorectal cancer cells with BCI resulted in antitumor effects associated with cell cycle arrest and induction of apoptosis. BCI exhibited strong cytotoxicity on DLD1, HT-29, and Caco-2 cells. BCI showed no significant interaction with irinotecan, but strongly attenuated the anticancer activity of oxaliplatin when administered together. Analysis of synergy potential further confirmed the antagonistic interaction between these two compounds. In silico investigation indicated CDK5 as a potential new target of BCI. Conclusions: Our studies point to the anticancer potential of BCI but note the need for a precise mechanism of action.
format Online
Article
Text
id pubmed-10526149
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-105261492023-09-28 In Vitro and In Silico Investigation of BCI Anticancer Properties and Its Potential for Chemotherapy-Combined Treatments Marciniak, Beata Kciuk, Mateusz Mujwar, Somdutt Sundaraj, Rajamanikandan Bukowski, Karol Gruszka, Renata Cancers (Basel) Article SIMPLE SUMMARY: BCI is an allosteric inhibitor of DUSP6 phosphatase, which is a negative regulator of MAPK kinases involved in numerous cellular processes such as proliferation, differentiation, and survival. These studies were designed to test the anticancer potential of BCI in colorectal cancer (CRC) cells and assess its interaction with chemotherapuetics such as irinotecan and oxaliplatin. In silico investigations were performed to indicate new possible molecular targets, which in the future will help toward understanding the precise mechanism of action. ABSTRACT: Background: DUSP6 phosphatase serves as a negative regulator of MAPK kinases involved in numerous cellular processes. BCI has been identified as a potential allosteric inhibitor with anticancer activity. Our study was designed to test the anticancer properties of BCI in colon cancer cells, to characterize the effect of this compound on chemotherapeutics such as irinotecan and oxaliplatin activity, and to identify potential molecular targets for this inhibitor. Methods: BCI cytotoxicity, proapoptotic activity, and cell cycle distribution were investigated in vitro on three colon cancer cell lines (DLD1, HT-29, and Caco-2). In silico investigation was prepared to assess BCI drug-likeness and identify potential molecular targets. Results: The exposure of colorectal cancer cells with BCI resulted in antitumor effects associated with cell cycle arrest and induction of apoptosis. BCI exhibited strong cytotoxicity on DLD1, HT-29, and Caco-2 cells. BCI showed no significant interaction with irinotecan, but strongly attenuated the anticancer activity of oxaliplatin when administered together. Analysis of synergy potential further confirmed the antagonistic interaction between these two compounds. In silico investigation indicated CDK5 as a potential new target of BCI. Conclusions: Our studies point to the anticancer potential of BCI but note the need for a precise mechanism of action. MDPI 2023-09-06 /pmc/articles/PMC10526149/ /pubmed/37760412 http://dx.doi.org/10.3390/cancers15184442 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Marciniak, Beata
Kciuk, Mateusz
Mujwar, Somdutt
Sundaraj, Rajamanikandan
Bukowski, Karol
Gruszka, Renata
In Vitro and In Silico Investigation of BCI Anticancer Properties and Its Potential for Chemotherapy-Combined Treatments
title In Vitro and In Silico Investigation of BCI Anticancer Properties and Its Potential for Chemotherapy-Combined Treatments
title_full In Vitro and In Silico Investigation of BCI Anticancer Properties and Its Potential for Chemotherapy-Combined Treatments
title_fullStr In Vitro and In Silico Investigation of BCI Anticancer Properties and Its Potential for Chemotherapy-Combined Treatments
title_full_unstemmed In Vitro and In Silico Investigation of BCI Anticancer Properties and Its Potential for Chemotherapy-Combined Treatments
title_short In Vitro and In Silico Investigation of BCI Anticancer Properties and Its Potential for Chemotherapy-Combined Treatments
title_sort in vitro and in silico investigation of bci anticancer properties and its potential for chemotherapy-combined treatments
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10526149/
https://www.ncbi.nlm.nih.gov/pubmed/37760412
http://dx.doi.org/10.3390/cancers15184442
work_keys_str_mv AT marciniakbeata invitroandinsilicoinvestigationofbcianticancerpropertiesanditspotentialforchemotherapycombinedtreatments
AT kciukmateusz invitroandinsilicoinvestigationofbcianticancerpropertiesanditspotentialforchemotherapycombinedtreatments
AT mujwarsomdutt invitroandinsilicoinvestigationofbcianticancerpropertiesanditspotentialforchemotherapycombinedtreatments
AT sundarajrajamanikandan invitroandinsilicoinvestigationofbcianticancerpropertiesanditspotentialforchemotherapycombinedtreatments
AT bukowskikarol invitroandinsilicoinvestigationofbcianticancerpropertiesanditspotentialforchemotherapycombinedtreatments
AT gruszkarenata invitroandinsilicoinvestigationofbcianticancerpropertiesanditspotentialforchemotherapycombinedtreatments